Krystal Biotech maintained at Buy; BofA raises target to $400
BofA Securities maintained Krystal Biotech at Buy and raised its price target to $400 from $392, per Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.